Zydus signs licensing agreement with Gilead to manufacture and market Remdesivir
Jun 13, 2020
Ahmedabad (Gujarat) [India], June 13 : Healthcare major Zydus Cadila has signed a non-exclusive licensing agreement with Gilead Sciences Inc for the manufacturing and distribution of Remdesivir, the investigational drug which has been issued an emergency use authorisation by the US Food and Drug Administration (FDA) to treat patients suffering from severe symptoms of novel coronavirus.